Crestwood Advisors Group LLC Has $355,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

Crestwood Advisors Group LLC trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 4,926 shares of the medical equipment provider’s stock after selling 337 shares during the period. Crestwood Advisors Group LLC’s holdings in Hologic were worth $355,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. General Partner Inc. acquired a new position in shares of Hologic during the fourth quarter worth approximately $26,000. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares in the last quarter. First Horizon Advisors Inc. lifted its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares in the last quarter. Covestor Ltd lifted its holdings in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the period. Finally, Loomis Sayles & Co. L P lifted its holdings in Hologic by 29.3% in the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after buying an additional 183 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Raymond James restated an “outperform” rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Finally, Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a report on Monday, February 3rd. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.77.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Stock Up 0.3 %

Shares of HOLX stock opened at $65.23 on Wednesday. The firm has a fifty day moving average of $69.62 and a 200-day moving average of $76.28. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12-month low of $62.69 and a 12-month high of $84.67. The company has a market capitalization of $14.64 billion, a price-to-earnings ratio of 20.58, a P/E/G ratio of 2.14 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.